Alpha 2.0
Login Register
» Authors » Martina Pennisi

Martina Pennisi

Explore the profile of Martina Pennisi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 754
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
Miguel-Angel Perales
Paolo Corradini
Annalisa Chiappella
Michael Scordo
Sean M Devlin
Anna Dodero
Silva Ljevar
Bianca D Santomasso
Gunjan L Shah
Craig S Sauter
Published In
Blood Adv
Leuk Lymphoma
Transplant Cell Ther
Bone Marrow Transplant
Nat Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study
Stella F, Pennisi M, Chiappella A, Casadei B, Bramanti S, Ljevar S, et al.
Transplant Cell Ther . 2025 Jan; PMID: 39870308
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in nonrelapse mortality, largely driven by infections, leading to the...
2.
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study
Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, et al.
Br J Haematol . 2024 Dec; 206(2):644-651. PMID: 39710966
Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral...
3.
EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy
Mao D, Reiner A, Chen X, Park J, Pennisi M, Perales M, et al.
Sci Rep . 2024 Nov; 14(1):29090. PMID: 39580601
Patients who develop chimeric antigen receptor (CAR) T-cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) frequently undergo evaluation with electroencephalography (EEG). We hypothesize that EEG features and Synek scale score, a...
4.
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma
Deschenes-Simard X, Pennisi M, Perales M, Shah G, Zelenetz A, Yahalom J, et al.
Leuk Lymphoma . 2024 Nov; 66(3):535-540. PMID: 39565041
No abstract available.
5.
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, et al.
Blood Cancer Discov . 2024 Jul; 5(5):318-330. PMID: 38953781
This real-world prospective observational study across 21 Italian centers (CART-SIE) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched...
6.
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D, et al.
Blood . 2024 Apr; 143(26):2722-2734. PMID: 38635762
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by...
7.
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, et al.
Leukemia . 2024 Mar; 38(5):1107-1114. PMID: 38459167
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate efficacy and safety of...
8.
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas
Dodero A, Bramanti S, di Trani M, Pennisi M, Ljevar S, Chiappella A, et al.
Br J Haematol . 2023 Sep; 204(1):151-159. PMID: 37690811
This study retrospectively evaluated the outcome of salvage therapy in 51 patients who failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B-cell lymphomas. Of these patients, 22 (43%) were enrolled...
9.
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
Stella F, Marasco V, Levati G, Guidetti A, De Filippo A, Pennisi M, et al.
Blood Adv . 2023 Jul; 7(19):5996-6004. PMID: 37450382
Infections are a major cause of morbidity and mortality during neutropenia after hematopoietic stem cell transplantation (HSCT). The use of a low-microbial protective diet (PD) in the peritransplantation period is...
10.
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy
Guidetti A, Dodero A, Lorenzoni A, Pizzamiglio S, Argiroffi G, Chiappella A, et al.
Cancer . 2022 Nov; 129(2):255-263. PMID: 36385707
Background: Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk...